Shots:
- The companies collaborated to evaluate IO’s IO102-IO103 + MSD’s Keytruda vs Keytruda alone in the P-III trial for patients with previously untreated unresectable or MM. Biomarker studies will also be conducted while IO will sponsor the trial & MSD will provide Keytruda
- The P-I/II trial of combination therapy in 30 patients with the same indication demonstrated ORR (73%) & CR rate (47%). The therapy can induce tumor regression & establish durable antitumor response while achieving a manageable tolerability profile
- IO102 & IO103 are the immune-modulatory vaccines targeting IDO & PD-L1. The therapy has received BTD from FDA for MM based on the P-I/II trial
Click here to read full press release/ article | Ref: PR Newswire | Image: IO Biotech
The post MSD Enters into a Clinical Collaboration with IO to Evaluate IO102-IO103 + Keytruda as 1L Treatment of Metastatic Melanoma first appeared on PharmaShots.
